Advanced search
Publication Cover
Postgraduate Medicine Volume 132, 2020 - Issue 2
Submit an article Journal homepage
2,965
Views
4
CrossRef citations to date
0
Altmetric
Clinical Features - Letter to the Editor

Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series

Maria Espositoa Department of Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, ItalyCorrespondence[email protected] [email protected]
,
Alessandro Giuntab Department of Dermatology, University of Rome “Tor Vergata”, Rome, Italy
,
Ester Del Ducab Department of Dermatology, University of Rome “Tor Vergata”, Rome, Italy
,
Valeria Manfredab Department of Dermatology, University of Rome “Tor Vergata”, Rome, Italy
,
Alfonso Troisic Department of Systems Medicine, International Medical School, University of Rome “Tor Vergata”, Rome, Italy
,
Luca Bianchib Department of Dermatology, University of Rome “Tor Vergata”, Rome, Italy
&
Maria Concetta Fargnolia Department of Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy
 show all
Pages 172-175 | Received 07 Oct 2019, Accepted 02 Jan 2020, Published online: 22 Jan 2020

References

  • Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401–407.
  • Kurd SK, Troxel AB, Crits-Christoph P, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population- based cohort study. Arch Dermatol. 2010;146:891–895.
  • Papp KA, Reich K, Paul C, et al. A prospective phase 3, randomised, double- blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175:273–286.
  • Chiricozzi A, Romanelli M, Saraceno R, et al. No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents. Expert Opin Drug Saf. 2016 Dec;15:1653–1659.
  • Kaushik SB, Lebwohl MG. Review of safety and efficacy of approved systemic psoriasis therapies. Int J Dermatol. 2019 Jun;58:649–658.
  • Esposito M, Saraceno R, Giunta A, et al. An Italian study on psoriasis and depression. Dermatology. 2006;212:123–127.
  • Patel N, Nadkarni A, Cardwell LA, et al. Psoriasis, depression, and inflammatory overlap: a review. Am J Clin Dermatol. 2017;18:613–620.
  • Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16:22–34.
  • Nadeem A, Ahmad SF, Al-Harbi NO, et al. IL-17A causes depression-like symptoms via NFκB and p38MAPK signaling pathways in mice: implications for psoriasis associated depression. Cytokine. 2017;97:14–24.
  • Lebwohl MG, Papp KA, Marangell LB, et al. Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials. J Am Acad Dermatol. 2018;78:81–89.
  • Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose- ranging study. Br J Dermatol. 2013;168:412–421.
  • Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371:326–338.
  • Galluzzo M, Talamonti M, De Simone C, et al. Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. Expert Opin Biol Ther. 2018;18:727–735.
  • van de Kerkhof PC, Griffiths CE, Reich K, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75:83–98.
  • Lebwohl M, Sherif B, Mollon P, et al. Secukinumab relieves pain and anxiety in psoriasis: results of two phase 3 trials. Presented at the 24th Annual Congress of the European Academy of Dermatology and Venereology; 2015 Oct 7–11; Copenhagen, Denmark.
  • Komori T, Otsuka A, Honda Y, et al. Exacerbation of depression in a psoriatic arthritis patient possibly induced by secukinumab. Eur J Dermatol. 2016;26:506–507.
  • Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21:111.
  • Basavaraj KH, Ashok NM, Rashmi R, et al. The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol. 2010;49:1351–1361.
  • Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80:1073–1113.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.